Teriparatide (human PTH 1–34 ) compensates for impaired fracture healing in COX-2 deficient mice

Abstract Genetic ablation of cyclooxygenase-2 (COX-2) in mice is known to impair fracture healing. To determine if teriparatide (human PTH 1–34 ) can promote healing of Cox-2 -deficient fractures, we performed detailed in vivo analyses using a murine stabilized tibia fracture model. Periosteal progenitor cell proliferation as well as bony callus formation was markedly reduced in Cox-2 −/− mice at day 10 post-fracture. Remarkably, intermittent PTH 1–34 administration increased proliferation of periosteal progenitor cells, restored callus formation on day 7, and enhanced bone formation on days 10, 14 and 21 in Cox-2- deficient mice. PTH 1–34 also increased biomechanical torsional properties at days 10 or 14 in all genotypes, consistent with enhanced bony callus formation by radiologic examinations. To determine the effects of intermittent PTH 1–34 for callus remodeling, TRAP staining was performed. Intermittent PTH 1–34 treatment increased the number of TRAP positive cells per total callus area on day 21 in Cox-2 −/− fractures. Taken together, the present findings indicate that intermittent PTH 1–34 treatment could compensate for COX-2 deficiency and improve impaired fracture healing in Cox-2- deficient mice.